Scancell, Neuphoria Agree to All-Share Merger

1. Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
2.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

A merger between two biotech companies is opening doors for potential growth, intriguing life sciences investors.

Key Takeaways

• Scancell Holdings Plc (SCNLF:OTC; SCLP:AIM) and Neuphoria Therapeutics Inc. (NEUP:NASDAQ) agreed to an all-share merger, with the combined company listing on Nasdaq under "SCLT" alongside Scancell's existing AIM listing.
• Existing Scancell shareholders will own ~85.5% of the combined company, with Neuphoria shareholders holding ~14.5%.
• Scancell secured commitments for up to $89 million in financing, including a $39.1 million private placement and a non-binding $25 million debt term sheet with BlackRock.
• Funds will support the Phase 3 registrational trial for iSCIB1+, Scancell's lead melanoma immunotherapy, which showed 77% progression-free survival at 22 months in combination therapy.
• Neuphoria stockholders will also receive contingent value rights tied to milestone payments from Neuphoria's partnered assets and IP monetization.
• The merger is expected to close in late Q4 2026, pending shareholder approval from both companies and NASDAQ/SEC listing requirements.

Neuphoria Becomes Scancell's Wholly Owned Subsidiary

On July 23, 2026, Neuphoria and Scancell announced a merger agreement under which Neuphoria will become a wholly owned subsidiary of Scancell. Each share of Neuphoria common stock will convert into Scancell ADSs at an exchange ratio of 37.77199, plus a contingent value right (CVR) tied to Neuphoria's existing partnered assets. Based on current assumptions, Neuphoria stockholders are expected to receive approximately 20.4 million ADSs, representing about 13.7% of Scancell's enlarged share capital at completion. The transaction has been approved by both boards but remains subject to shareholder approval at each company, along with SEC review of Scancell's NASDAQ listing.

Neuphoria's decision centers on Scancell's lead asset, iSCIB1+, which holds FDA fast-track designation and has shown durable efficacy in combination with ipilimumab and nivolumab, with further survival data expected from the Phase 2 SCOPE study within 12 months. Dr. Phil L'Huillier, Scancell's CEO, said in the release: "This transaction will establish Scancell on NASDAQ and enables access to U.S. investors and the broader U.S. life sciences sector for the capital we need to execute the registrational Phase 3 study for iSCIB1+ in advanced melanoma. We believe the compelling data from our Phase 2 SCOPE study demonstrating benefit to patients across multiple clinical endpoints warrants pressing forward to evaluate the product in a registrational randomized study. We strongly believe this transaction creates meaningful near- and long-term value for shareholders of both companies.”

Financial highlights of the transaction include:

• All-share Merger: The share consideration for the merger consists of 20,414,065 ADSs (representing an aggregate of 204,140,654 consideration shares) which are expected to represent approximately 13.7% of Scancell’s enlarged issued ordinary share capital following completion
• Contingent Value Rights (CVRs): Neuphoria stockholders will also receive contingent value rights representing the right to receive future conditional cash payments (if any) based on the achievement of certain milestones relating to Neuphoria’s partnered assets, any monetization of certain of Neuphoria's intellectual property rights and upon receipt of payment of an Australian R&D tax credit in respect of the year ended 30 June 2026
• Financing: subject to completion of the U.S. Listing Transactions (expected to occur in late Q4 2026), the Group is expected to have a pro forma net cash balance of approximately US$79.1 million (before transaction costs), taking into account the proceeds of the financing and inclusive of the closing cash in Neuphoria:

• Private Placement: Private Placement to raise US$39.1 million through the issue of 324,190,865 new ordinary shares (including ordinary shares to be represented by ADSs) and non-voting ordinary shares. Placement Price of US$0.1205 per ADS, ordinary share or non-voting ordinary share
• K. Placing and Retail Offer: U.K. Placing to raise approximately US$12.0 million and a retail offer to raise up to approximately a further US$3.0 million at 9 pence per ordinary share, being the GBP equivalent of the placement price, neither being conditional on the U.S. Listing Transactions
• Debt Financing: non-binding term sheet entered into with certain funds and accounts managed by BlackRock, Inc. (BLK:NYSE) for up to US$25 million of new debt financing.

• Scancell shareholders, together with the investors in the private placement, the U.K. placing, and the retail offer, are expected to own approximately 86.3% of the completion ordinary share capital and approximately 88.9% of the total outstanding issued share capital of Scancell, including ordinary shares and the non-voting ordinary shares (together the "Completion Total Share Capital"). Neuphoria stockholders are expected to own approximately 13.7% of the completion ordinary share capital and 11.1% of the Completion Total Share Capital.

Prior to the merger, Neuphoria has stopped development of its lead candidate, BNC210, in social anxiety disorder after its Phase 3 AFFIRM-1 trial missed its primary and secondary endpoints in October 2025, and has since been conducting a strategic review. As of March 31, 2026, Neuphoria held US$19.4 million in cash, had no ongoing revenue, and reported a net loss of US$0.5 million for the quarter. Under the terms of the deal, Scancell will not Neuphoria's non-partnered assets further, with the CVRs instead capturing any value from Neuphoria's existing licensing agreements, including its collaboration with Merck Sharp & Dohme and a Pfizer license related to KAT6, along with a pending Australian R&D tax credit.

The transaction is expected to close in late Q4 2026, ahead of a planned 10-for-1 share consolidation at Scancell to align its ADS price with U.S. market expectations. Closing requires payment of at least US$75 million of the financing package.

Neuphoria is a U.S. clinical-stage biotech company focused on treating neuropsychiatric disorders. Scancell is a late-stage clinical biotech company based in the U.K. that is focused on developing active immunotherapies designed to stimulate durable anti-tumor responses.

Pharma Funding Falls, Cancer Cases Rise

In February 2026, Iqvia discussed the global pharma market projection for 2026, noting that total drug usage is expected to surpass four trillion doses daily by 2030. They wrote, "The largest drivers of medicine spending growth through the next five years will continue to be the use in developed markets of innovative therapeutics, especially in oncology, immunology, diabetes, and obesity."

Pharma sector funding fell between 2024 and 2025, according to a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor.  He wrote that pharma funding had fallen from 2024 but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."

The global cancer treatment sector, unfortunately, shows no signs of shrinking. A March 26, 2026, article by Kinjel Shah for Yahoo Finance claimed that cancer incidences were rising. He quoted the American Cancer Society as expecting 2.1 million new cancer cases and over 626,000 cancer-related deaths in 2026. However, technology is ever-evolving to keep up with the disease.

Shah wrote, "Emerging technologies such as genomic sequencing, artificial intelligence, and machine learning are accelerating biomarker discovery, enhancing patient stratification, and enabling earlier and more accurate diagnoses. While a universal cure remains out of reach, consistent improvements in survival rates and patient outcomes across multiple cancer types highlight the tangible benefits of these advances, particularly when combined with earlier detection and intervention."

This innovation comes at a price. In February 2026, Keith Speights wrote an article for The Motley Fool discussing rising care costs, stating that cancer treatments in the U.S. cost roughly US$200 billion in 2020 but are expected to increase to more than US$245 billion by 2030.

BCG talked about trends biopharma companies need to be aware of in 2026 in order to stay competitive, saying, "Near term, companies need to continue to innovate to decrease the complexity and cost of these therapies, and governments can find ways to incentivize and pay for them. The longer-term challenge for companies is to factor operational and economic considerations into R&D decision making earlier, ensuring that trial designs match real-world usage, indication sequences match opportunity, and endpoints enable market access."

Wainwright Calls Merger a Constructive Outcome

After news of the merger, Joseph Pantginis, Ph.D., of H.C. Wainwright & Co. wrote about the company on July 27, 2026. Pantginis did not offer a price target and maintained a "Neutral" rating for Neuphoria, arguing that: "We view the merger as a constructive outcome from the strategic review following the AFFIRM-1 failure." Pantginis continued: "The 14.5% ownership stake in the combined company gives Neuphoria shareholders exposure to Scancell's oncology pipeline, while the CVRs preserve potential upside from Neuphoria's partnered assets."

Ownership & Share Information¹

Neuphoria Therapeutics Inc. has a market cap of US$20.81 million, with 5.40 million shares outstanding. The company's 52-week range is US$3.19-US$21.40. Institutions own 34.56% of shares, while Strategic Investors own 4.30%. Management & Insiders own 3.41% of shares, and the remaining 57.73% of shares are Retail.

Frequently Asked Questions

Q:  What is an all-share merger?

A: An all-share merger is a deal in which shareholders of one company receive shares in the combined company instead of cash. After the merger closes, former shareholders become part owners of the newly combined business.

Q:  What is a Phase 3 registrational trial?

A: A Phase 3 registrational trial is a large clinical study designed to provide the evidence regulators need to decide whether to approve a new treatment. Positive results from this stage can support an application for regulatory approval, making it one of the final steps before a medicine may reach patients.

Q: What are contingent value rights (CVRs)?

A: Contingent value rights (CVRs) are financial rights that may provide shareholders with additional payments if certain future milestones are achieved, such as regulatory approvals, product sales, or licensing deals. These payments are not guaranteed and depend on specific conditions being met.

Q: Why do biotech companies merge?

A: Biotech companies may merge to strengthen their finances, combine research programs, access new investors, or speed up the development of promising medicines. A merger can also help fund expensive late-stage clinical trials and prepare a company for commercialization.

Q: What does FDA Fast Track designation mean?

A: Fast Track is a program created by the U.S. Food and Drug Administration (FDA) to help speed the development and review of treatments for serious diseases that address unmet medical needs. It does not guarantee approval, but it can allow companies to work more closely with the FDA and potentially shorten the review process.